THEARE CHALLENGING LEADER INSPIRING EXCELLENCE
ASIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLOGY
ON TO DETAIL DILIGENT CARING DYNAMIC PEOPLE FOCUSE
IEALTHCARE ETHICAL ACCURATE EFFICIENT CHALLENGIN
PLE FOCUSED PROGRESSIVE COMPASSIONATE HEALTHCAS
EFFICIENT CHALLENGING LEADER INSPIRING EXCELLENCE
ASSIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLOGY
OF TECHNOLOGY ETHICAL ACCURATE EFFICIENT CHALLENGIN
OF HEALTHCARE INSPIRING EXCELLENCE ATTENTION TO DETAIL
ONAL CUTTING EDGE FIRST TECHNOLOGY ETHICAL ACCURATE
OFFICIENT CHALLENGING LEADER INSPIRING EXCELLENCY
OFFICIENT CHALLENGING DISCUSSIONATE PROFESSION

USED PROGRESSIVE COMPASSIVARE LEADER INSPIRING EXCELL ONAL CUTTING EDGE FIRST TECH ENT CARING DYNAMIC PEOPLE LACCURATE EFFICIENT CHALLEN RE PEOPLE FOCUSED PROGRESS

E EFFICIENT CHALLENGING LEADER INSPINING EXCEL ASSIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLO ON TO DETAIL DILIGENT CARING DYNAMIC PEOPLE FOCUS ECHNOLOGY ETHICAL ACCURATE EFFICIENT CHALLENGIN LE FOCUSED PROGRESSIVE COMPASSIONATE **PROFESSION** ER INSPIRING EXCELLENCE ATTENTION TO DETAIL DILIGE TING EDGE FIRST TECHNOLOGY ETHICAL ACCURATE EFFICIEI IG DYNAMIC HEALTHCARE PEOPLE FOCUSED PROGRESSIV CAL ACCURATE EFFICIENT CHALLENGING LEADER INSPIRIN GRESSIVE COMPASSIONATE PROFESSIONAL CUTTING EDG CELLENCE ATTENTION TO DETAIL DILIGENT CARING DYNAM. T TECHNOLOGY ETHICAL ACCURATE HEALTHCARE EFFICIEN DYNAMIC PEOPLE FOCUSED PROGRESSIVE COMPASSIONAL EFFICIENT CHALLENGING LEADER INSPIRING EXCELLENCE SSIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLOG V TO DETAIL DILIGENT CARING DYNAMIC PEOPLE FOCUSE THEARE FEHICAL ACCURATE EFFICIENT CHALLENGIN



Q3 2020 Investor Presentation

As of 30 September 2020

Disclaimer



Disclaimer and important information in relation to this presentation

This presentation has been prepared solely for use as earnings presentation of Dr. Sulaiman Al Habib Medical Services Group Company (the "Company"). By attending or by reading this presentation, you agree to be bound by the following limitations.

The information contained in this presentation is for background purposes only and does not purport to be comprehensive and has not been independently verified, nor does it constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation to buy or subscribe for any securities in any jurisdiction, or a recommendation in respect of buying, holding or selling any securities.

No representation or warranty, express or implied, is made as to, and no reliance should be placed by any person for any purpose on the information contained in this presentation, fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation.

The information in this presentation is subject to change, update, revision, verification and amendment and such information may change materially. HMG is under no obligation to update or keep current the information contained in this presentation and any opinions expressed in it is subject to change without notice. This presentation has not been approved by any competent regulatory authority.

This presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Any investor should make his investment decision, solely on the basis of the information that is contained in the prospectus (the "Prospectus") published by the "Company". The contents of this presentation are not to be construed as legal, or financial.

The distribution of this presentation may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein come should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This presentation may include statements that are, or may be deemed to be, "forward-looking statements" with respect to the Company's financial position, results of operations and business and certain of the Company's plans, intentions, expectations, assumptions, goals and beliefs. The contents of this presentation have been prepared by and are the sole responsibility of the Company.

Presenting team











AGENDA

- **Growth strategy**
- **How we performed**

Spotlight

Technology and medical excellence

Appendix #1

About HMG

Appendix #2

Summarized financials



Equity story and strategy

A well-defined strategy enhanced by our core values




Vision

To be the most trusted healthcare provider in medical excellence and patient experience globally

Mission


To develop and operate state of the art medical facilities and provide innovative healthcare services to create value for people

Strengthening the core




Patient centric healthcare

Expanding the reach



Organic growth while considering inorganic opportunities

Broadening the service




Creation of new business lines

Key messages

A best-in-class healthcare leader with a clear growth strategy






Best-in-class

- Regional integrated healthcare provider with
 25-year track record
- Resilient revenues and stable gross margins supported by economies of scale, strong cash flow management and healthy balance sheet
- Defined strategy to strengthen core, expand reach and broadening the services



Catalysts for value creation

- Technology: Pioneer in healthcare technology, award-winning hospital information system (HIS) & other 11 Technology Products.
- PPP Programs: 7 MoH ICU locations under management (including Tele ICU) for 189 beds and working to build more in the pipeline
- Robust expansion plan: 3 new hospitals under construction, construction of one additional hospital to start in 2021, expansion of HMG Solutions



Efficiency drivers

- Efficient cash conversion cycle: shortest CCC in the industry, proactive collection process
- Cost efficiency: economies of scale and cost efficiency on a growing patient volume base
- Technology to drive operational efficiency: best in class HIS, patients and physicians apps and rapidly growing business solutions including special focus on automation of services


HMG is contributing to the goals of Vision 2030



KSA has set a target to increase private sector participation in the healthcare industry to 35% by 2020



Areas of focus for privatization



How has HMG positioned itself to participate?

Intensive Care Units (ICUs)

- Operating ICU beds in 7 MoH hospitals
- Managing the largest Tele-ICU Command
 Center in the world

(Guinness World Record 2019)

Solutions

- Implementing VIDA in 17 MoH hospitals
- Management, operation and maintenance of PACS infrastructure systems in 11 MoH hospitals

Home Healthcare

Providing home healthcare services to General
 Department of Medical Services at the Ministry of Interior

Business structure

A fully integrated healthcare services provider









Pharmacies

HMG Solutions

- 7 hospitals in Saudi Arabia and Dubai
- 1,900+ beds and 1,370+ clinics
- 1 medical center in Bahrain through management agreement
- **13k+** staff, **2,750+** physicians

- Outpatient pharmacies as part of the hospitals
- 13 pharmacies in Saudi Arabia
- 1 pharmacy in Dubai
- 400+ employees
- E-Pharmacy

- Cloud Solutions: technology Arms including HIS, e-medicine, mobile app & other Applications
- PPP Programs: Operating Intensive Care Units for others
- Home Healthcare services
- MD LAB for advance laboratory services


Where we operate

C. سليـ ان الـ حبـيب

DR SULAIMAN AL HABIB

medical group المجموعة الطبية

With total built-up area of 689,000+ m2, HMG owns most of its hospital properties







Solidifying our market leadership through robust expansion plan





North Riyadh



100% Ownership



SAR 669.7 mn



SAR 2.2 bn

Construction



2023 Expected



500 Beds

Land



300

Clinics



Design

Excavation



Construction



Excavation

- Raft 100% Complete (68,397.19 m3 concrete)
- 100,970Sqm Slap finish
- Horizontal waterproofing completed



Total workforce

- 742 HMG Engineering and Contracting **Staff**
- 1.1 million Safe working hours
- Zero incidents to date





Solidifying our market leadership through robust expansion plan





South-West Jeddah



50% Ownership



SAR 91 mn Land



SAR 1.5 bn Construction



2023

Expected



330 Beds



245

Clinics



Design

Excavation

MoH license

Construction




Excavation

- Shoring Wall 100% completed 731 meter
- Excavation Works **214,181/283,272** cum 75.6 %
- Waterproofing of piles **487/2084** piles



Total workforce

- 548 HMG Engineering and Contracting **Staff**
- 965,350k+ Safe working hours
- Zero incidents to date





Solidifying our market leadership through robust expansion plan





New Takhassusi Maternity and Pediatric Hospital



100% Ownership



SAR 80.8 mn Land



SAR 391 mn





2024 Expected

145 Beds



100

Clinics



Design

Excavation

MoH license

Construction



Excavation

Excavation Works 75% completed



Design

- Architectural design 100 % completed
- Structural design 100% completed



Total workforce


- 548 HMG Engineering and Contracting **Staff**
- 965,350k+ Safe working hours
- Zero incidents to date





Solidifying our market leadership through robust expansion plan







Medical Center at Diplomatic Quarter



Leased Agreement



10 Years





2021 Expected





Highlights: Q3 2020



Operations

Strategic partnership with Dubai Government Workshop

Spreading awareness of breast cancer

Medical excellence

Issue of Dr. Sulaiman Al Habib Medical Journal

5 Published
Research

20 Scientific Research work conducted

Technology

Launch of HR platform **Mowadhafi Service**



Mobile application Q3 2020

Total Download 735k+ downloads Growth 45%

Booked Appointments 354k+ appointments Growth 87%

Transactions 97m+ transactions Growth 388%

Habib Live Care 35k+ transactions

E-Pharmacy 15k+ transactions










Continuous Medical Education for 2,340+ participants


246 CPR course with **1,243**


800+ undergraduate trainees trained from **12** university


Financial highlights: Q3 2020





















Healthy balance sheet / 9-month


Liabilities







Assets




























Low leverage levels / 9-month





Total liabilities and equity


SAR million


















Total cash dividends for shareholders: Q3 2020





Cash dividends / Q3-2020			
Total distributed dividends	SAR 210 million		
% of capital	6% (equivalent to SAR 0.60 per share)		
Eligibility date	29 October 2020		
Date of distribution	15 November 2020		

Total cash dividends for shareholders / 9M 2020				
Total distributed dividends	SAR 525 million			
% of capital	15% (equivalent to SAR 1.50 per share)			

Investor Relations: IR Optic

Listening to our capital markets partners



We want to know your views...

Ongoing effort to ensure high levels of disclosure and transparent communications

Our IR team, will conduct an independent Capital Markets
Perception Study

We would greatly appreciate your feedback, which will be requested on a **non-attributable** basis

Findings will be provided to Management and the Board

Outputs from the report will be reflected in our IR strategy

Objective: Investor and analyst feedback on

- IR program
- Investment case
- Business strategy
- Operational model
- Outlook

Respecting your time and your preferences

We fully appreciate the time constraints facing the investment community

You will have the option to participate through an **online survey** which should take no more than **10-12 minutes**

OR our IR team will be available to speak to you to discuss your views on a **call** lasting approximately **20 minutes**.

An IR representative will be in touch with you over the coming days

Do not hesitate to contact us, at investor.relations@drsulaimanalhabib.com, if you would prefer not to be contacted.


If you would be **happy to conduct the interview via phone**, please do also let us know



Developing cutting edge technology

Pioneer in award-winning hospital information system and applications in the MENA region







15+ Years of
experience
in deploying technology
solutions in healthcare
domain



11 Products




27 Digital hospitals




15 Clients







70% Saudization



400+ Employees



23 International partnerships



4 University student internships

Pioneer in healthcare technology

Better medical outcomes, exceptional patient experience, and advanced operational practices





E-medicine

Tele-ICU

- The largest in the world (Guinness World Record), with 796 beds
- First in MENA working 24/7
- Scalable to manage 1,000+ beds

Tele-radiology:

- Improving efficiency and quality of care
- Central reporting 24/7

Tele-medicine

Enabling second opinion through robotics

Tele-health

 Enabling home health care and tele-health, fully integrated with medical equipment



HIS (VIDA)

- First-of-its-kind electronic portal
 - Helps in storing and managing medical procedures, diagnostics, and analysis
- Integrates healthcare provision stages in a paperless environment
- Web-based (Cloud-based)
- Built using the industry's best practices and healthcare standards such as HL 7, ICD 10, CPT
- Achieved HIMSS stage 6 accreditation
- 17 MoH Hospitals



Mobile application


medical record anywhere anytime

Patients

- Unique patient experience
- Built using the latest Technologies

Physicians

Continuity of care



Pioneer in healthcare technology (cont'd)

Introducing the latest medical equipment









MRI

The first in the region with lightweight coil design and noise cancelation that provides comfort to the patient

CT Scan

High definition imaging for all body parts with exceptionally low dose of X-ray to the patient

CATH Lab

All heart related diagnoses in high resolution with lowest possible X-ray dose to the patient

Pioneer in healthcare technology (cont'd)

Introducing the latest medical equipment









CSSD

The best technology in the region to disinfect and sterilize surgical instruments

Laboratory

Fully digital and integrated laboratories, allowing for fast and accurate diagnosis without human intervention

IVF Lab

Safe environment for embryos and highest number of cycle with comparable probabilities of successful pregnancy to international benchmarks

Attracting and retaining top talent

Our employees are our most valuable assets





15+ average years' experience



4+ years physician retention rate



100+ recruiting offices




90+ nationalities



14 fellowship programs to train 50+ Saudi physicians






Western (including North America and UK)



Other



Saudi Arabia



Strong track record in construction and ramp-up



On average, opening a new hospital every 29 months, completing construction in 33 months and ramping-up in 16 months

Hospital		Beginning of construction	Completion of construction	Positive EBITDA	
Olaya Medical Center		1993	1995	24 months	
Dubai outpatient	THE REAL PROPERTY OF THE PARTY	2005	2007	22 months	
Maternity		2006	2008	14 months	
Qassim		2006	2009	16 months	
Al Rayyan	E THE RESERVE TO THE	2006	2010	10 months	
Takhassusi		2007	2012	10 months	
Spinal		2007	2010	12 months	
Dubai inpatient		2012	2015	10 months	
Suwaidi		2013	2016	22 months	
Khobar		2016	2019	Opened in Q2 2019	

Diverse board of directors

Our success is driven by our people



3 Non-Executives



Dr. Sulaiman Al Habib Chairman

- Founder of HMG
- Previously chairman of the Medical Committee in Riyadh Chamber of Commerce



Saleh Al Habib **Board Member**

- Board member, Al-Andalus Real **Estate Company**
- Board member, Hamat Holding Company



Nabeel AlAmoudi **Board Member**

- Member of Saudi Aramco's **Board of Directors**
- Was Saudi Arabia's transport minister





Nasser Al Haqbani **Board Member and CEO**

- Board member, Saudi Center for **Patient Safety**
- Member of the Board of Trustees of the Saudi Commission for Health Specialties



Faisal Al Nassar Board Member and CFO

- Board member in all subsidiaries of the Group
- Previously CFO at ACWA Power Holding



3 Independents



Mazen Al Rumaih Vice Chairman

- Chairman, Saudi Fransi Capital
- Previously board member of the CMA



Obaid Al Rasheed Board Member

- Chief Executive Officer, Arab National Bank
- Board member, Saudi Chemical Company



Ziyad Al Saleh Board Member

- Board member, JP Morgan Saudi Arabia
- Board member, Gulf Union **Insurance Company**



Hesham Al Habib Board Member and VP, Business Dev.

Board member and member of the Audit Committee, Kingdom Holding Company, Hamat **Holding Company**

Experienced senior management

Highly experienced, high caliber management





Nasser Al Hagbani
Chief Executive Officer

Core functions



Abdulwahab
Al Abdulwahab
Chief Operating Officer



Abdullah Al Harbash Vice President of Physicians Affairs



Sulaiman Al Majid
Vice President of Medical
and Nursing Affairs



Sulaiman Al Tuwaian
Vice President of
Hospital Affairs

Corporate functions



Faisal Al Nassar Chief Financial Officer



Hesham Al Habib
Vice President of
Business Development



Saud Al Arifi
Vice President of General
Counsel of the Group



Mustafa Al Amri
Vice President of
Logistics Management

Independent functions



Riyadh Al Ateeq
Director Pharmaceutical
Facilities

General Director



Abdullelah Al Mayman
Chief Executive Officer of
Cloud Solutions



Vimal Subramanian
Head of Internal Audit

Hospitals

Medical Director

Executive Director

Q3 2020 Investor Presentation



Summary: Balance sheet

As at 30 September 2020



SAR million	As of Sep 2020	As of Sep 2019	Change %
Current Assets	3,266	2,989	9.25%
Inventory	381	296	28.70%
Investments	37	40	-7.02%
Fixed Assets	5,323	5,142	3.52%
Total Assets	9,007	8,467	6.37%
Current Liabilities	1,653	1,495	10.55%
Non-Current Liabilities	2,368	2,381	-0.57%
Shareholders Equity	4,811	4,394	9.49%
Minority Interests	175	197	-10.92%
Total Liabilities and Shareholder Equity	9,007	8,467	6.37%

Summary: Income statement

As at 30 September 2020



SAR million	Q3 2020	Q3 2019	Change%	YTD 2020	YTD 2019	Change%
Revenue	1,623.9	1,226.7	32.4%	4,170.3	3,611.8	15.5%
Cost of revenue	(1,065.0)	(877.8)	21.3%	(2,851.7)	(2,524.0)	13.0%
Gross profit	558.9	349.0	60.2%	1,318.6	1,087.9	21.2%
Selling and marketing expenses	(104.9)	(47.7)	119.7%	(180.6)	(133.3)	35.4%
G&A expenses	(130.1)	(108.8)	19.6%	(352.2)	(350.3)	0.5%
Operating income	323.9	192.5	68.3%	785.8	604.2	30.1%
Other income, net	11.9	16.0	(25.5%)	42.1	48.7	(13.7%)
Share in net income of associates	2.6	0.0	na	(1.8)	2.0	(189.6%)
Finance charges	(10.8)	(5.1)	111.4%	(37.9)	(16.6)	128.9%
Minority interest	2.2	10.5	(79.4%)	21.7	22.1	(1.9%)
EBT	329.8	213.9	54.2%	809.9	660.5	22.6%
Zakat	(31.0)	(15.9)	95.2%	(72.2)	(60.5)	19.4%
Net income*	298.8	198.0	50.9%	737.6	600.1	22.9%

^{*} Attributable to Equity holders of the Parent

Summary: Cash flow statement





SAR million	9M 2020	9M 2019	Change %
EBT before minority and Zakat	788.2	638.4	23.5%
Depreciation	238.6	184.7	29.2%
Accounts Receivable	291.4	(274.1)	(206.3%)
Inventory	(84.9)	(39.9)	112.5%
Prepaid Expenses	(2.4)	(53.3)	(95.4%)
Accounts Payable	(43.7)	(16.7)	162.3%
Other Changes in Oper. Activity	215.7	151.7	42.2%
Purchases of Fixed Assets	(417.1)	(499.7)	(16.5%)
Other Changes in Investing Act.	(599.0)	2.5	na
Increase in Debts	93.1	321.2	(71.0%)
Other Changes in Financing Act.	(391.6)	(588.8)	(33.5%)
Cash at Beginning of Period	1,196.7	1,369.1	(12.6%)
Cash at End of Period	1,284.9	1,195.1	7.5%







Dr. Sulaiman Al Habib Medical Services Group

Tel: +966 11 525 9999

Fax: +966 11 462 0096

Email: investor.relations@drsulaimanalhabib.com

P.O. Box 301578 Riyadh 11372, Kingdom of Saudi Arabia www.hmg.com

